Overview

Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Status:
Completed

Trial end date:
2021-05-26

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well ruxolitinib phosphate works in treating patients with diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma that has returned (relapsed) or that does not respond to treatment (refractory) after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Phase:

Phase 2

Details

Lead Sponsor:

University of Nebraska

Collaborators:

Incyte Corporation
National Cancer Institute (NCI)